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                                    Abstract 
 
Background: There is limited knowledge about prognosis of selected breast 
cancer subtypes among very young women  
Patients and Methods: We explored patterns of recurrence by age according 
to four immunohistochemically-defined tumor subtypes: triple negative, HER2 
positive (and) endocrine receptor absent, Luminal A and Luminal B (ER-
positive and/or PR-positive and either HER2-positive and/or high Ki67)  in 
2970 premenopausal  patients with  pT1-3, pN0-3 and M0 breast cancer. 
Results: Patients below 35 years of age (315, 11%) presented a significantly 
increased risk of recurrence and death (HR=1.65, 95%CI 1.30-2.10 and 
HR=1.78, 95%CI 1.12-2.85, respectively) when compared with older patients 
(2655, 89%) with similar characteristics of disease. This was true considering 
patients with luminal B (HR 1.62, 95%CI, 1.21-2.18, for DFS; HR 2.09, 
95%CI, 0.96-4.53, for OS)  and with triple-negative (HR 2.04, 95%CI, 1.11-
3.72, for DFS; HR 2.20, 95%CI, 1.10-4.41, for OS)  breast cancer, observing 
the highest risk of recurrence in the younger patients with HER2 positive 
breast cancer (HR 2.37, 95% CI, 1.12-5.02),  when  compared with older 
patients.  
Conclusions: Very young patients with triple negative, luminal B, or HER2 
positive breast cancer have a worse prognosis when compared with older 
patients with similar characteristics of disease. 
  .                                  
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                            1. Introduction 
 
Breast cancer at a young age has been reported to have a more aggressive 
biological behaviour compared with the disease in older patients ( 1-6). 
Walker evaluated pathological features, oestrogen and progesterone receptor 
status, proliferation as determined by Ki-67 labelling and the presence of c-
erbB-2 and p53 protein of one hundred and sixty-three breast carcinomas 
occurring in women aged between 26 and 44 years comparing with a control 
group of carcinomas from women in the 50-67 years age group. In this analysis 
carcinomas occurring in women aged under 35 years had a significantly high 
incidence of being poorly differentiated and of having high proliferation rates. 
This group also had a significantly high incidence of p53 protein staining. 
Carcinomas in the under 30 years age group had a lower incidence of oestrogen 
and progesterone receptor positivity. No differences were found in c-erbB-2-
positive staining between the groups (1)  
Kroman investigated whether young age at diagnosis is a negative prognostic 
factor in primary breast cancer and how stage of disease at diagnosis and 
treatment influences such an association with a retrospective cohort study based 
on a population based database. Subjects were 10356 women with primary 
breast cancer who were less than 50 years old at diagnosis. As result, overall, 
young women with low risk disease who did not receive adjuvant treatment had 
a significantly increased risk of dying; risk increased with decreasing age at 
diagnosis (adjusted relative risk: 45-49 years (reference): 1; 40-44 years: 1.12 
(95% confidence interval 0.89 to 1.40); 35-39 years: 1.40 (1.10 to 1.78); <35 
years: 2.18 (1.64 to 2.89). However, no similar trend was seen in patients who 
received adjuvant cytotoxic treatment. The increased risk in younger women 
who did not receive adjuvant treatment compared with those who did remained 
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when women were grouped according to presence of node negative disease and 
by tumour size (4). 
Colleoni evaluated biological features and stage at presentation for 1427 
consecutive premenopausal patients aged ≤50 years with first diagnosis of 
invasive breast cancer referred to surgery at the European Institute of Oncology 
from April 1997 to August 2000.  A total of 185 patients (13%) were aged <35 
years (‘very young’) and 1242 (87%) were aged 35–50 years (‘less young’. In 
this analysis, compared with less young patients, the very young patient group 
had a higher percentage of tumours classified as ER negative (P <0.001), PgR 
negative (P = 0.001), higher expression of Ki-67 ≥20% of cells stained; 62.2% 
versus 53%, (P <0.001), vascular or lymphatic invasion (48.6% versus 37.3%, P 
= 0.006), and pathological grade 3 (P <0.0001). There was no difference 
between the two groups for pT, pathological tumor size (pN) and number of 
positive lymph nodes. 
Authors concluded that compared with less young premenopausal patients, very 
young women have a greater chance of having an endocrine-unresponsive 
tumour, and are more likely to present with a higher grade, more extensively 
proliferating and vessel invading disease. Pathological tumour size, nodal status 
and number of positive axillary lymph-nodes have a similar distribution among 
the younger and the older cohorts, thus not supporting previous data indicating 
more advanced disease in younger patients at diagnosis of operable disease (6). 
Although controversy exists about the definition of ‘‘very young age’’ or 
“very young patients”.and different  cut off have been proposed  it has been 
showed that younger age is  associated with a more unfavourable prognosis and 
that the relationship between recurrence hazard and age was continuous with a 
4% decrease in recurrence and a 2% decrease in cancer-specific death for every 
year of increase in age (7).  In a recent publication of Han W. for patients aged 
<35 years, the risk of death rose by 5% for every 1-year reduction in age, 
whereas there was no significant change in death risk with age in patients aged 
35–50 years. (8). 
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Chemotherapy was commonly offered to the younger patients due to the fact 
that adjuvant therapies were prescribed in the past according to risk factors: the 
higher the risk the more intensive the treatment.  
However, endocrine therapies appear to be an essential component of an 
effective adjuvant therapy program and retrospective analyses suggest that the 
endocrine effects of chemotherapy alone are insufficient for the younger 
patients with endocrine-responsive breast cancer (9). Whether use of complete  
endocrine therapy (e.g. ovarian function suppression plus tamoxifen) may be 
sufficient for these patients is a hypothesis that has not been tested adequately. 
Recently, the Early Breast Cancer Overview group reported a meta-analysis 
of individual patient data on the use of LHRH agonists. In patients 40 years old 
or younger, the addition of an LHRH agonist to chemotherapy significantly 
reduced the risk of recurrence and death (HR 0.74; p = 0.01) versus 
chemotherapy alone. This effect was greatest in the group 35 years old or 
younger, whereas in the group older than 40 years, the addition of an LHRH 
agonist did not improve outcome. When chemotherapy alone was compared 
with LHRH agonist with or without tamoxifen in younger premenopausal 
patients with hormone receptor-positive tumors, the endocrine therapy 
improved outcome (mortality HR 0.82; P = 0.15) (10). 
 
1.1 Molecular classification of Breast Cancer 
Breast cancer is a molecularly heterogeneous disease. Evidence from gene 
expression microarrays suggests the presence of multiple molecular subtypes 
of breast cancer. Gene expression studies have identified five molecularly 
distinct subtypes of breast cancer that have prognostic value across multiple 
treatment settings (11-13). Using complementary DNA (cDNA) microarrays 
representing 8,102 human genes to characterize gene expression patterns in a 
set of 65 surgical specimens of human breast tumours from 42 different 
individuals, Perou et al. demonstrated that the phenotypic diversity of breast 
tumours was associated with corresponding gene expression diversity. From 
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the genes in the 65 tissues samples, the investigators selected a subset of 456 
genes, which were termed the “intrinsic” gene subset, and consisted of genes 
with significantly greater expression variation between different tumours than 
between paired samples from the same tumour. Using this subset, the authors 
were then able to identify 4 different molecular subtypes of breast cancer: 
estrogen receptor (ER)-positive/luminal-like, basal-like, Erb–B2-positive (ie, 
tumours that overexpress ERBB2-associated genes but do not express genes 
that define the luminal subtype), and normal breast. Subsequent data expanded 
the classification to distinguish between luminal A and luminal B. Sorlie et al. 
examined a subset of 49 patients with locally advanced breast cancer who 
were treated with doxorubicin and had a median follow-up of 66 months and 
found that the recurrence-free survival and overall survival differed 
significantly among the breast cancer subtypes, with the luminal A tumours 
having the longest survival times, the basal-like and HER2-positive subtypes 
having the shortest survival times, and the luminal B tumors having an 
intermediate survival time (11,14,15). The expression of ER-associated genes 
characterizes the luminal breast cancers, with luminal B tumours having 
poorer outcomes than luminal A tumours. Recent study defined the best Ki67 
index cut point to distinguish luminal B from luminal A tumours (16). In this 
study, authors developed a clinically practical immunohistochemistry assay to 
distinguish luminal B from luminal A tumors and investigated its ability to 
separate tumors according to breast cancer recurrence-free and disease-
specific survival. Tumors from a cohort of 357 patients with invasive breast 
carcinomas were subtyped by gene expression profile. The best Ki67 index cut 
point to distinguish luminal B from luminal A tumors was 13.25%. In an 
independent cohort of 4046 patients with breast cancer, 2847 had hormone 
receptor – positive tumors, then HER2 immunohistochemistry and the Ki67 
index were used to subtype these 2847 tumors;  Luminal B and luminal – 
HER2-positive breast cancers were statistically significantly associated with 
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poor breast cancer recurrence-free and disease-specific survival in all adjuvant 
systemic treatment categories (16). 
Moreover, data from the study BCIRG 001 were analyzed dividing tumours in 
four subtypes according to immunohistochemical evaluation of ER, PgR, Ki-67 
and HER2. The four subtypes were Luminal A, Luminal B, HER2 and triple 
negative; this classification appeared useful to define different prognostic 
subtypes with different relationship with adjuvant treatment received (17).  
Although this "new" classification has limitations, it could be useful in the 
clinical practice, allowing not only a more accurate prognosis in breast cancer 
patients but also a selective treatment for each predefined subtype.  
 
We therefore investigated the most recently available details of biological 
characteristics and prognosis of very young patients (<35 years of age) with 
operable breast cancer and the effects of adjuvant treatment programs 
according to immunohistochemically (IHC) defined subsets. 
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                                  2 Patients and methods 
 
We prospectively collected information on all consecutive premenopausal 
breast cancer patients operated at the European Institute of Oncology between 
April 1997 and December  2004. 
Data on the patient’s medical history, concurrent diseases, surgery, 
pathological evaluation, and results of staging procedures (blood chemistry, 
hematological values, bone scan, chest film and upper abdominal ultrasound 
examination) were required. Pathological assessment included evaluation of 
the primary tumour size, histological type and of lymph nodes status including 
a sentinel node biopsy (18), when applicable. Tumour grade was evaluated 
according to Elston and Ellis (19) and peritumoral vascular invasion (PVI) was 
assessed according to Rosen (20) Estrogen (ER) and progesterone receptor 
(PgR) status, Ki-67 labeling index (assessed with the MIB 1 monoclonal 
antibody), and HER2/ neu over-expression (routinely performed since 1999) 
were evaluated immunohistochemically as previously reported (21). The 
threshold for ER and PgR positivity was 1% and for Mib1 positivity 20%, as 
previously published (21). The threshold for ER and PgR was based on 
published data indicating a different pattern of outcome according to the 
degree of potential endocrine responsiveness (22, 23). 
 
 
2.1 Statistics 
 The Fisher exact test and the Mantel-Haenszel Chi-Square test for trend 
were used to assess the association between respectively, categorical and 
ordinal variables. The primary endpoints were the incidence of locoregional 
relapse (LRR), distant metastasis (DM), breast cancer related event  (BCE), 
disease-free survival (DFS) and overall survival (OS). DFS was defined as the 
length of time from the date of surgery to any relapse (including ipsilateral 
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breast recurrence), the appearance of a second primary cancer (including 
contralateral breast cancer), or death, whichever occurred first. OS was 
determined as the time from surgery until the date of death (from any cause) or 
the date of last follow-up. Cumulative incidence and survival plots according 
to age were drawn using the Kaplan-Meier method. The log-rank test was used 
to assess the survival difference between strata. Multivariate Cox proportional 
hazard regression analysis was used to assess the independent prognostic 
significance of various clinical and histopathological characteristics of the 
tumor on event free or overall survival. Factors included in multiple regression 
analyses included tumor diameter, lymphnodal involvement, ER and PgR 
expression, Ki-67 expression, Her2/neu overexpression, vascular invasion, 
grade, histotype and immunohistochemical classification:  
 
• Luminal A (ER>0 or PgR>0) and (Ki67<14%) and (Her2Neu 0/+/++) 
• Luminal B (ER>0 or PgR>0) and ((Ki67≥14%) or (Her2Neu +++)) 
• HER2 (ER=0 and PgR=0) and (Her2Neu +++) 
• Triple Negative (ER=0 and PgR=0) and (Her2Neu 0/+/++) 
 
In patients with Luminal B tumors and with Triple Negative tumors, we 
assessed the effect of adjuvant therapy (respectively hormonal and 
chemotherapy) on outcome.  All analyses were performed with the SAS 
software, version 8.2 (Cary, NC).  
 
2.2 Treatment received  
All patients received adequate local treatment (breast conserving surgery or 
total mastectomy) plus axillary sentinel lymph node biopsy (SLNB) or 
complete axillary dissection. SLNB was followed by axillary dissection only if 
the sentinel node contained metastasis or minimal node involvement. The SLN 
was identified and isolated using a gamma probe as a guide as previously 
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published (24). Postoperative breast irradiation (RT) was proposed to all the 
patients that received breast-conserving surgery (25). Systemic adjuvant 
therapy was recommended according to St. Gallen’s treatment guidelines (25-
27). For patients with endocrine responsive disease, adjuvant endocrine 
therapy alone was indicated (the combination of tamoxifen for 5 years plus 
LH-RH analogue for a minimum of 2 years) (21). In patients at higher risk (i.e. 
occurrence of peritumoral vascular invasion, younger age, large tumors) and/or 
with features of uncertain endocrine responsiveness [(e.g. low levels of ER 
positivity, lack of PgR expression, overexpression of HER2/neu, and increased 
proliferation markers, (28)], chemotherapy was added. Anthracycline 
containing chemotherapy was considered as the first option in patients with 
higher risk (i.e. AC, adriamycin and cyclophoshamide, for four courses (29); in 
case of comorbidities or patients preferences classical CMF (oral 
cyclophosphamide, methotrexate and fluorouracil) for a duration of three to six 
courses was considered (30). In case of endocrine non-responsive disease 6 
months of chemotherapy was commonly indicated [classical CMF for six 
courses or AC for four courses followed by classical CMF for three courses 
(23) according to the degree of the patient risk] 
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                                 Results 
 
A total of 12,281 patients with invasive breast cancer were referred to the 
interdisciplinary evaluation and their data were included in the institutional 
database between 1997 and 2004. 
We selected 4.524 consecutive premenopausal patients, of age 50 or less. 
We subsequently excluded 1,213 patients, 473 that presented with 
neoadjuvant therapy, 52 had a previous other primary, 136 bilateral tumours 
and 552 operated with recurrent or metastatic tumours and 341 for lack of 
information on endocrine receptor status, ki76 or Her2Neu which did not allow 
to perform the biological classification of the tumors.  
The final analysis is based on data from 2970 patients 
The number and characteristics of evaluable patients are given in Table 1  
 
 
 
 
 
 
 Table 1: Characteristics of breast cancer patients according to               
age at diagnosis  
 
 
 All 
Age at diagnosis 
 
p- 
 Patients <35 ≥35 value 
ALL 2970 315 (100.0) 2655 (100.0)  
  
  
 
Histology 
   
 
Ductal 2398 283 (89.8) 2115 (79.7)  
Lobular 
  253     7 (  2.2)   246 (  9.3)  
Ductal+lobular 
  120     4 (  1.3)   116 (  4.4)  
Other 
  199   21 (  6.7)   178 (  6.7) <.0001 
Tumour size     
≤1cm 
  515   33 (10.5)   482 (18.2)  
 15 
1-2cm 1286 129 (41.0) 1157 (43.6)  
2-4cm 
  906 115 (36.5)   791 (29.8)  
>4cm 
  227   34 (10.8)   193 (  7.3) <.0001 
Unknown  
    36     4 (  1.3)     32 (  1.2)  
Tumour grade     
G1 
  432   21 (  6.7)   411 (15.5)  
G2 1348   99 (31.4) 1249 (47.0)  
G3 1083 180 (57.1)   903 (34.0) <.0001 
Unknown  
  107   15 (  4.8)     92 (  3.5)  
Number of positive 
nodes 
 
  
 
None 1454 146 (46.3) 1308 (49.3)  
1-3 
  996 107 (34.0)   889 (33.5)  
4-9 
  324   33 (10.5)   291 (11.0)  
10 or more   186   29 (  9.2)   157 (  5.9) 0.08 
pNx 
    10 -     10 (  0.4)  
PVI     
Absent 1951 189 (60.0) 1762 (66.4)  
Present 1015 126 (40.0)   889 (33.5) 0.02 
Unknown  4 
 
    0 (  0.0) 
 
      4( 0.2) 
 
 
ER     
Absent 
  413   72 (22.9)   341 (12.8)  
Present 2557 243 (77.1) 2314 (87.2) <.0001 
PgR     
Absent 
  613 101 (32.1)   512 (19.3)  
Present 2357 214 (67.9) 2143 (80.7) <.0001 
Ki67     
<20% 
1173   71 (22.5) 
1102 
(41.5) 
 
≥20% 
1786 239 (75.9) 
1547 
(58.3) 
<.0001 
Unknown  
    11     5 (  1.6) 
      6 
(  0.2) 
 
Her2/Neu     
0/+/++ 2144 208 (66.0) 1936 (72.9)  
+++ 
  451   66 (21.0)   385 (14.5) 0.003 
Unknown  
  375   41 (13.0)   334 (12.6)  
Molecular 
classification    
 
Luminal A 
  592   29 (  9.2)   563 (21.2)  
Luminal B 1986 217 (68.9) 1769 (66.6)  
 16 
HER2 
  141   18 (  5.7)   123 (  4.6)  
Triple Negative 
  251   51 (16.2)   200 (  7.5) <.0001 
Surgery     
Quadrantectomy 2194 227 (72.1) 1967 (74.1)  
Mastectomy  
  776   88 (27.9)   688 (25.9) 0.44 
Sentinel node biopsy     
No 1123 157 (49.8)   966 (36.4)  
Yes 1847 158 (50.2) 1689 (63.6) <.0001 
                                          Table 1 (cont’)    
In the ‘very young’ group, when compared with the ‘less young’ patients, 
there were higher percentages of tumours of high grade (57.1% versus 34.0%; 
P < 0.0001).and tumours classified ER (22.9% versus 12.8%; P < 0.0001) and 
PgR (32.1% versus 19.3%; P < 0.001) absent,  
Moreover in younger patients  (aged <35 years ) there were higher percentage 
of tumors with perivascular invasion ( 40.0% vs 33.5% P= 0.02),and HER2-
overexpression (21% versus 14.5% P=0.003) than patients with age 35-50 
years. 
According to the immunohistochemical classification, in the group of 
patients aged < 35 years there were less tumors defined as Luminal A (9.2% 
versus 21.2%) and more triple negative tumors  (16.2% versus 7.5%, 
P<0.0001) than older patients .  
 
                                      3.1 Adjuvant treatment 
 
As shown in Table 2, very young patients in the Luminal A subtype  received 
more LHRH agonist alone but less Tamoxifen alone (p=0.036) than older 
patients; no difference was showed about the chemotherapy; in the  Luminal B 
subtypes there were more patients who received  LHRH alone and the 
combination of  Tamoxifen and  LHRH agonist than patients 35-50 years old 
(p<.0001);  while , in the same subtype,  younger patients received more 
chemotherapy than older patients , above all anthracyclines-based regimen ( 
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p<0.0001). No significant difference was showed about treatments of the 
patients in the HER2 and Triple-negative subtypes. 
 
 
Table 2: Adjuvant treatment modalities in breast cancer patients according 
 to age at diagnosis and molecular classification 
 
 Luminal A Luminal B 
 <35 35-50 P* <35 35-50 P* 
ALL  29 563  217 1769  
       
Hormonotherapy       
None 2 12  16 80  
TAM alone 1 84  8 428  
LHRH alone  3 18  29 48  
TAM+LHRH 22 431  162 1117  
OTHER/NOS 1 18 0.036 2 96 <.0001 
Chemiotherapy       
None 22 430  45 702  
Antracycline 7 102  132 776  
CMF 0 17  21 197  
Other/NOS 0 14 0.76 19 94 <.0001 
 HER2 Triple Negative 
 <35 35-50 P* <35 35-50 P* 
ALL  18 123  51 200  
       
Hormonotherapy       
None 18 114  45 193  
TAM alone 0 2  1 1  
LHRH alone  0 3  5 2  
TAM+LHRH 0 3  0 4  
OTHER/NOS 0 1 1.00 0 0 0.006 
Chemiotherapy       
None 1 11  3 13  
Antracycline 14 81  21 87  
CMF 1 8  22 88  
Other/NOS 2 23 0.90 5 12 0.79 
    *Fisher’s exact test 
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3.2 Clinical Outcomes according to age and 
immunohistochemical (IHC) classification 
 
3.2.1. Locoregional Relapse (LRR),  Distant Metastases (DM), Breast Cancer 
related Events( BCE)  
 
As shown in the Figure 1, incidence of LRR , DM and BCE were different 
between the four IHC subtypes  both in very young and 35-50 years old group;  
HER2 appeared the subtype with the highest incidence of events.  
 
 
 
Figure 1: Outcome of breast cancer patients according to age at 
diagnosis and molecular classification. 
 
 
<35 years 35-50 years 
Lo
co
re
gi
o
n
al
 
re
la
ps
e 
 19 
Di
st
an
t m
et
as
ta
si
s 
Br
ea
st
 
ca
n
ce
r 
re
la
te
d 
Figure 1(cont’)  
 
 
When we analyzed data to compare very young with older patients, we 
showed,  for all biological subtypes,  a statistically significant difference of 
incidence of LRR, DM and BCE (p=0.0001)  between patients below 35 years 
and 35-50 years old patients. At multivariate analysis , age < 35 years  was a 
risk factor for an increased incidence of locoregional relapse (HR=1.78, 1.19-
2.67), distant metastasis (HR=1.55 , 1.11-2.17) and breast cancer related events 
(HR=1.70 , 1.33-2.18) (Figure 2).  
Analyzing each subtype, our data did not showed a difference of LRR, DM 
and BCE in the Luminal A subtype. The difference between very young 
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patients and older patients appeared evident in the Luminal B subtype with an 
increased risk of LRR (HR=1.82 ,1.13-2.94), DM (HR=1.57, 1.04-2.37) and 
BCE (HR=1.71, 1.26-2.32) (Figure 2).  
In the HER2 and Triple Negative subtype, very young patients were at 
increased risk of LRR, DM and BCE with a statistically border-line 
significance. (Figure 2).  
 
 
Figure 2: Cumulative incidence (%) of locoregional relapse, 
distant metastases and breast cancer related events in breast cancer 
patients according to age at diagnosis and molecular classification. 
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HR=1.55 (1.11-2.17) HR=1.70 (1.33-2.18) HR=1.78 (1.19-2.67) 
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Figure 2 (cont’) 
Legend: Hazards Ratio (HR) and 95% confidence intervals obtained from 
multivariable Cox proportional hazards regression model adjusted for 
hormonal receptor status, proliferative index (ki-67), peritumoural vascular 
invasion, tumour size, nodal status and Her2Neu overexpression, 
chemiotherapy (none/ CMF/Anthracycline containing therapy, other regimen) 
and hormonotherapy (none, LHRH or Tamoxifen alone, LHRH+Tamoxifen, 
other regimen). 
 
 
HR=1.57 (1.04-2.37) HR=1.71 (1.26-2.32) HR=1.82 (1.13-2.94) 
HR=2.77 (1.09-7.04) HR=2.14 (0.98-4.70) HR=2.78 (0.72-10.7) 
HR=1.44 (0.64-3.27) HR=1.94 (1.04-3.61) HR=1.70 (0.53-5.44) 
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3.2.2 Survival Outcomes: Disease-Free Survival (DFS), Overall Survival 
(OS) 
 
DFS and OS were statistically different between the four IHC defined 
subtypes both in the group of very young and in the group of older patients; 
HER2 and Triple negative were the subtypes with the lowest survival in both 
age groups (Figure 3).  
 
 
Figure 3: Outcome of breast cancer patients according to age at 
diagnosis and molecular classification. 
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In the Figure 4 is shown the comparison of survival outcomes between very 
young and older patients. Analysis for all biological subtypes showed a 
statistically significant difference of DFS and OS (p=0.0001) between patients 
below 35 years and patients aged 35-50. At multivariate analysis , age < 35 
years  was a risk factor for increased recurrence (HR=1.65, 1.30-2.10) and 
death (HR=1.78, 1.12-2.85).  
Very young patients with tumors classified as Luminal B, HER2 and Triple 
Negative were at increased risk of recurrence HR=1.62, 1.21-2.18, HR=2.37, 
1.12-5.02, HR=2.04, 1.11-3.72, respectively) compared with older patients. 
Very young patients in HER2 subtype were at increased risk of death , but wit 
no statistically significance difference; while, in the Luminal B and Triple 
negative subtypes, patients below 35 years had a 2-fold higher risk of death 
compared with older patients (HR=2.09, 95%CI 0.96-4.53; HR=2.20, 95%CI 
1.10-4.41, respectively) 
 
 
Figure 4: Disease free survival and overall survival in breast cancer 
patients according to age at diagnosis and molecular class 
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Figure 4 (cont’) 
 
Legend : Hazards Ratio (HR) and 95% confidence intervals obtained from 
multivariable Cox proportional hazards regression model adjusted for 
hormonal receptor status, proliferative index (ki-67), peritumoural vascular 
invasion, tumour size, nodal status and Her2Neu overexpression, 
chemiotherapy (none/ CMF/Anthracycline containing therapy, other regimen) 
and hormonotherapy (none, LHRH or Tamoxifen alone, LHRH+Tamoxifen, 
other regimen). 
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3.2.3 Clinical outcomes according to hormonal therapy  
An analysis was conducted to evaluate the impact of different treatments on 
disease-free survival in two groups of patients, very young patients (below 35 
years ) and older patients ( between 35 and 50 years). 
A statistically significant reduced DFS was showed in the young patients 
with tumors defined as Luminal B who received tamoxifen or LHRH analogue 
alone versus the combination of the two drugs (p=0.0367)(Figure 5). This 
result was confirmed at multivariate analysis, with an increased risk of 
recurrence for patients who received  LHRH agonist or Tamoxifen alone 
versus the combination of the same drugs (HR=1.88,1.00-3.55) (Figure 5);.  
In the group of older patients with age more than 35 years no difference was 
found between the different hormonal therapies in terms of disease-free 
survival ( p= 0.7; HR=0.97, 0.70-1.34) (Figure 5) 
Figure 5: Disease free survival according to selected adjuvant 
therapies in breast cancer patients according to age at diagnosis and 
molecular classification 
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Hazards Ratios and 95% confidence intervals (CI) for LHRH or Tamoxifen 
alone vs. LHRH+Tamoxifen (HR1) and for CMF vs. anthracycline containing 
therapy (HR2) obtained from multivariable Cox proportional hazards 
regression model adjusted for proliferative index (ki-67), peritumoural 
vascular invasion, tumour size, nodal status and Her2Neu overexpression.  
HR1=0.97 (0.70-1.34) HR1=1.88 (1.00-3.55) 
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4 Discussion 
 
The present study provides useful insights into the treatment of breast cancer 
because it is based on a large population of very young patients with breast 
cancer evaluated within the context of a central pathology analysis using 
modern classification according to IHC defined subtypes 
In fact, as recently showed,  an IHC profile based on the degree of expression 
of ER, PgR, Ki-67 and HER2 might identify  subgroups of breast cancer 
patients who will respond to different systemic adjuvant treatments (17). 
However, limited information is available in the adjuvant setting on the 
outcome and responsiveness to therapy in the very young  population. 
according to molecular or immunohistochemical (IHC) classification. 
Data from Carolina Breast Cancer Study were analyzed to determine 
population-based distributions and clinical associations for breast cancer 
subtypes with IHC surrogates  applied to 496 incident cases of invasive breast 
cancer; study showed that  the IHC subtypes differed significantly by age 
(P_.001) and menopausal status (P=.008) so that patients with  luminal A and 
B tumours were older than the other patients; moreover  this study showed that 
breast cancer–specific survival differed by subtype (P<0..001), with shortest 
survival among HER2+/ER− and basal-like subtypes.(31).  
Study of Bauer et al, evaluated features  of 6370 triple-negative breast 
cancers compared with 44,704 other breast cancers. One of the study results 
was that women with triple-negative breast cancers were significantly more 
likely to be under age 40 (odds ratio 1.53) (32).  
Our study showed that in the group of patients aged < 35 years there were 
less tumors defined as Luminal A (9.2% versus 21.2%) and more triple 
negative tumors  (16.2% versus 7.5%, P<0.0001) than older patients . 
Moreover our data confirmed other studies results, for both the two groups of 
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young patients ( <35 and 35-50 years) that is,  the HER2 and Triple negative  
are the subtypes with the worst prognosis( 31, 17). 
More interesting, beside the feature of a more aggressive disease presentation 
which reflects on patients outcome, the results of the present study led to the 
identification of himmunoistochemically definded subtypes within the group of 
very young patient which require adjuvant tailored therapies. In fact, our study 
showed that very young patients with tumors classified as Luminal B, HER2 
and Triple Negative were at increased risk of LRR, DM, BCE, recurrence and 
death, compared with older patients.  
Previous analyses evaluated prognosis of young patients focusing on the only 
well known prognostic and predictive factor, hormone receptor status (33,34).  
Recent researches permitted to understand the molecular complexity of breast 
cancer, defining so some different genetic portraits, but analysis of gene 
expression is not still now a useful tool for the physician. Therefore , also if the 
IHC classification could be only a surrogate of molecular and genetic 
definition of breast cancer, it can be much more useful in the clinical practice, 
allowing a more accurate prognosis and selection of  treatment for each 
predefined subtype in breast cancer patients  
Results of the present study support the issue that younger patients   require 
adjuvant tailored therapies.  
. The results of this analysis are important for clarifying the role of adjuvant 
tamoxifen in younger premenopausal patients and provide information on the 
importance of ovarian function suppression and its impact on the efficacy of 
tamoxifen..  
The effect of chemotherapy-induced amenorrhea have been studied although 
it remains controversial.  
As previously proposed, endocrine effects of chemotherapy are probably 
insufficient for young women with ER-positive breast cancer. A large analysis 
on 7,631 patients who were treated with chemotherapy alone showed markedly 
increased risks of relapse for young patients with ER–positive tumours 
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compared with older patients (9). In a retrospective analysis of 3,700 
premenopausal patients involved in IBCSG trials I, II, V and VI patients 
treated with adjuvant cyclophosphamide, methotrexate, and fluorouracil 
chemotherapy alone , the failure to achieve chemotherapy-induced amenorrhea 
was associated with an increased risk of relapse. ( 35 ) 
In the study of Ahn et al, hormonal therapy with tamoxifen, after 
chemotherapy, added significant survival benefit with a hazard ratio of 0.61 for 
overall survival in patients between 35 and 50 years of age with positive or 
unknown hormone receptor status, but there was no significant additional 
benefit from tamoxifen alone  in patients younger than 35 years, ( 34 ). The 
Early Breast Cancer Overview group reported a meta-analysis of individual 
patient data on the use of LHRH agonists. In patients 40 years old or younger, 
the addition of an LHRH agonist to chemotherapy significantly reduced the 
risk of recurrence and death (HR 0.74; p = 0.01) versus chemotherapy alone. 
This effect was greatest in the group 35 years old or younger, whereas in the 
group older than 40 years, the addition of an LHRH agonist did not improve 
outcome. ( 10 ). Similarly, data from the NSABP indicating an increased risk 
(HR=1.91; 95% CI 1.21 to 3.01; P = 0.006) for younger versus older patients 
with endocrine responsive disease treated with tamoxifen alone (36). 
In the present analysis  we found that the combination of LH-RH analogue 
with tamoxifen  was significantly correlated with improved DFS for very 
young  patients (aged < 35 years) in the Luminal B subtype, if compared with 
either tamoxifen or LH-RH analogue  alone , thus supporting a role for 
complete endocrine therapy in the adjuvant treatment of young premenopausal 
patients. We limited the analysis of the effect of hormonotherapy on DFS to 
women with Luminal B since there were few events in Luminal A.  
The question of whether additional benefit can be obtained from ovarian 
suppression in premenopausal patients receiving tamoxifen is now being 
directly addressed by the global Suppression of Ovarian Function Trial 
coordinated by the IBCSG on behalf of the Breast International Group and the 
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North American Breast Cancer Intergroup. The Suppression of Ovarian 
Function Trial compares tamoxifen alone versus ovarian function suppression 
plus tamoxifen versus ovarian function suppression plus exemestane for 
patients with steroid hormone receptor–positive tumors who remain 
premenopausal after adjuvant chemotherapy or for whom tamoxifen alone is 
considered reasonable treatment option.(37).  
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5 Conclusions 
The present study indicate that the outcome of very young patients with  
early breast cancer is worse in selected tumor subtypes identified by IHC. 
Moreover the results herein presented support the hypothesis that the progress 
in the adjuvant treatment of very young patients requires study of tailored 
treatments in specific “niches” of patients. It should however be emphasized 
that the tumor subtypes identified in the present analysis include heterogeneous 
groups of tumors, and that the identification of further tumor subtypes 
amenable to targeted treatments represents a research priority.  
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